Clinical trial

Regional Adipose Tissue Characteristics in Type II Diabetes

Recruiting now · Not applicable · 1 countries · Registry ID NCT06599047

Recruiting nowNot applicableObservational

What this study is about

Fat tissue in different parts of the body has different characteristics. Several studies have associated abdominal fat to an increased risk for multiple metabolic diseases, such as type 2 diabetes and cardiovascular disease, compared with fat located under the skin at the hips and thighs. However, the investigators do not know how the abdominal fat causes or contributes to the development of these diseases or how the development of these disease may in turn cause or contribute to changes in the fat tissue. The general objective of this study is to understand these mechanisms. To investigate these questions, the study will recruit 140 participants, both men and women aged 18-65 years. The participants will be divided into three groups: 40 people with obesity, 40 with diabetes, and 60 lean individuals. Participants will be recruited from patients at the CIUSSS du Nord-de-l'Île-de Montréal - Hôpital du Sacré-Coeur de Montréal who are awaiting bariatric or general abdominal surgery, as well as from the general population in the Montreal area.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years

SexAll

Healthy volunteersAccepted

ConditionObesity and Type 2 Diabetes, Bariatric Patients Undergoing Bariatric Surgery, Adipose Tissue Dysfunction Type 2 Diabetes Mellitus Bariatric Surgery, Adipose Tissue Inflammation

Full registry criteria

Inclusion Criteria: * Men, premenopausal and postmenopausal females between 18-65 years * Anticipating having bariatric surgery (participants with obesity) or general surgery in the abdominal area (normal weight participants) with a duration of less than 1.5 hours. * BMI 30 kg / m2 (participants with obesity) * Weight Stable for a minimum of two months prior to the first pre-op visit Exclusion Criteria: * Smoking * Renal impairment defined by creatinine clearance; 60 ml/minute * Uncontrolled hypothyroidism * No comorbidity other than diabetes type II Exceptions: controlled hypertension, hypothyroidism controlled, controlled dyslipidemia * Use prescribed medication that affect our outcomes E.g. Exceptions include metformin, DPP-4 inhibitors, inhibitors of the α-glucosidase, hypotensive with a stable dose for 3 months lipid lowering with a stable dose for 3 months.

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Immune Cell Quantification5 years

Flow Cytometry will be used to quantify immune cells in the fat tissue.

Pre-adipocytes and adipocyte characteristics5 years

Cellular characteristics such as proliferation, differentiation and cellular senescence will measured.

Blood Inflammatory Markers5 years

The inflammatory cytokines (e.g. IL6, TNFα), chemokines (e.g. monocyte chemoattractant protein-1), genomics, and adipokines (e.g. leptin, adiponectin) in blood and adipose tissue via PCR, luminex or ELISA will be measured

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Concordia University (School of Health)🇨🇦 Montreal, Quebec, Canada

Open map

Sylvia Santosa, R.D, PhDContact

Email · Call 514.848.2424

Study contactContact

Muhammad Ilyas Nadeem, PhD CandidateContact